TrialBlood advances2022

Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma.

Richard T Maziarz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.